tbuckley/cabot-search huggingface dataset:
Abstract 19207: The Third Time’s a Charm: Factor Analysis, Psychometric Testing, and Update of the Atlanta Heart Failure Knowledge Test
Authors: Carolyn M Reilly, Brittany Butts, Melinda Higgins, Sandra B Dunbar
Journal: Circulation (2016)

Background and Objective:  Since first published in 2009, the Atlanta Heart Failure Knowledge Test (AHFKT) has been demonstrated to be a reliable and valid instrument, used in multiple studies and translated into more than 15 languages. Given advances in heart failure (HF) self-care, we proposed to reevaluate the psychometric properties of the AHFKTv2 in a larger sample and update the instrument.   Methods:  The 30 questions of the AHFKT (at 5th grade reading level) are focused on 5 knowledge domains essential for HF self-care: pathophysiology, nutrition, behavior, medicine, and symptoms. Demographic, clinical, and baseline AHFKTv2 data from 4 intervention studies in persons with HF were combined for this analysis (N=284). Characteristics of the sample and by group were analyzed using descriptive statistics; validity testing with t tests and Pearson  r  correlations, Mann-Whitney two-group tests, and Spearman’s rho; and tetrachoric correlations computed as the basis for reliability calculations and factor analysis.   Results:  Participants were 22 to 84 years of age, 66% African American, 63% male, and 94% NYHA class II-III. Participants had a mean AHFKT score of 80.6% (±11%). Hypotheses that higher education level would be associated with higher knowledge (t=-2.7, p   Conclusion:  Comprehensive psychometric evaluation of the AHFKTv2 revealed confirmation of internal consistency reliability and validity, and provided direction for production of the AHFKTv3 available for use in research and clinical practice.
Selection Does Not Equate Consumption
Authors: Juliana F. W. Cohen, Scott Richardson, Eric B. Rimm
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 11457: Surveillance of Perioperative Myocardial Injury With Cardiac Troponins Influences Medical Management at the Time of Hospital Discharge
Authors: Marina Zakharova, Francesca Mazzulla, Thomas Rector, Edward O McFalls, Demetris Yannopoulos, Emmanouil Brilakis, Santiago Garcia
Journal: Circulation (2015)

Background: Current AHA/ACC guidelines recommend against the use of cardiac troponins (cTn) for the surveillance of perioperative myocardial injury (PMI) in asymptomatic patients. We hypothesized that surveillance of PMI with cTnI would lead to initiation or intensification of medical therapies for coronary artery disease (CAD). Methods: The Cardiac Remote Ischemic Preconditioning Prior to Elective Vascular Surgery (CRIPES, NCT 01558596) is an ongoing prospective, randomized, sham-controlled phase 2 trial using remote ischemic preconditioning prior to elective vascular procedures. The primary efficacy end-point is the proportion with and magnitude of postoperative increases in cTnI. Cardiac troponins, measured before and after surgery, were available to treating clinicians. Increases above ≥ 0.01 μg/L in the perioperative period were considered clinically significant. Intensification of medical therapy was defined as initiation of aspirin (ASA) or initiation/increases in the dose of angiotensin-converting-enzyme inhibitors (ACEI)/angiotensin-receptor blockers, statins, or beta-blockers. Results: Between June 2011 and April 2015, a total of 185 patients (mean age 68±7, 100% male) were enrolled in the trial. A total of 28 patients (15%) had significant increases in cTnI after vascular surgery and 38 (20.5%) had their medical therapies intensified in the perioperative period. Baseline utilization of medical therapies was high: ASA 86%, statins 75%, beta-blockers 65%, ACEI 48%. The most frequent change in medical therapy in the perioperative period was initiation of ASA (9%). Among patients with substantial increases in cTnI 11 (39%) had intensification of medical therapy versus 27 (17%) in patients with no or smaller increases in cTnI (p=0.02). Using logistic regression analysis to control for subject’s age, history of CAD, CHF, diabetes, high-risk surgery, and revised cardiac risk index, a cTnI increase &gt; 0.01 μg/L remained associated with intensification of medical therapy (odds ratio: 3.2, 95% CI: 1.3-8.3. p=0.014). Conclusions: Among patients undergoing vascular surgery, surveillance of cTn in the perioperative period has value, by altering the clinician’s decisions to either initiate or intensify medical therapies for CAD.
mTORC2 Promotes Tumorigenesis via Lipid Synthesis
Authors: Yakir Guri, Marco Colombi, Eva Dazert, Sravanth K. Hindupur, Jason Roszik, Suzette Moes, Paul Jenoe, Markus H. Heim, Isabelle Riezman, Howard Riezman, Michael N. Hall
Journal: Cancer Cell (2017)
Recent advances in intradural spinal tumors
Authors: Muhammad M Abd-El-Barr, Kevin T Huang, Ziev B Moses, J Bryan Iorgulescu, John H Chi
Journal: Neuro-Oncology (2017)

Intradural spinal tumors are rare tumors of the central nervous system. Due to the eloquence of the spinal cord and its tracts, the compact architecture of the cord and nerves, and the infiltrative nature of some of these tumors, surgical resection is difficult to achieve without causing neurological deficits. Likewise, chemotherapy and radiotherapy are utilized more cautiously in the treatment of intradural spinal tumors than their cranial counterparts. Targeted therapies aimed at the genetic alterations and molecular biology tailored to these tumors would be helpful but are lacking. Here, we review the major types of intradural spinal tumors, with an emphasis on genetic alterations, molecular biology, and experimental therapies for these difficult to treat neoplasms.
Search Images and Extrapolation Risk—Reply
Authors: Deborah Grady, Leslee Subak
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Robot-assisted Retrohepatic Inferior Vena Cava Thrombectomy: First or Second Porta Hepatis as an Important Boundary Landmark
Authors: Baojun Wang, Hongzhao Li, Qingbo Huang, Kan Liu, Yang Fan, Cheng Peng, Liangyou Gu, Xintao Li, Gang Guo, Rong Liu, Minggen Hu, Guodong Zhao, Hongguang Wang, Fengyong Liu, Jiang Xiong, Xu Zhang, Xin Ma
Journal: European Urology (2017)
The Future of Radiology
Authors: Barton F. Branstetter
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients with locally advanced, K-ras-mutated rectal cancer (LARC): A phase I/II trial (SAKK 41/08).
Authors: Roger Von Moos, Dieter Koeberle, Ralph C. Winterhalder, Richard Cathomas, Roman Ignaz Inauen, Daniel Rudolf Zwahlen, Arnaud Roth, Daniel Helbling, Oliver Gautschi, Daniela Baertschi, Reto Kuehne, Thomas Von Briel, Anja Grzesiczek, Panagiotis Samaras, Attila Kollar, Dirk Klingbiel, Kathrin Zaugg
Journal: Journal of Clinical Oncology (2012)

3595 Background: 40% of patients (pts) with LARC present with K-ras mutation. Sor is an inhibitor of ras/raf and of VEGFR. Furthermore Sor has radiosensitizing effects. These facts build a strong rationale to use Sor in combination with preoperative RT and Cape in pts with K-ras mutant tumors. Methods: Pts with K-ras mutated mrT3-4 and / or mrN+, M0 disease were recruited in cohorts of 7 pts per dose level (DL). Dose limiting toxicity (DLT) was defined as any G3 or higher non hematological toxicity (tox) or haematological tox during ≥ 7 days, which are possibly, probably or definitely related to trial treatment occurring during and up to 4 weeks after last administration. If ≤ 2 out of 7 pts experienced a DLT, then the next cohort was treated at a higher dose level. If &gt; 2 out of 7 pts suffered from a DLT, this DL would be considered too toxic and a dose level below would be tested in the next cohort. The highest dose level with ≤ 2 out of 7 pts experienced a DLT would be recommended for the phase II part. In all dose levels RT was given in 25 fractions at 1.8Gy (45Gy). Results: In 8 centers in Switzerland a total of 21 pts in 3 cohorts have been treated in the phase 1 study. After observing severe skin toxicity and diarrhea (2 pt with skin toxicity G3, one patient (pt) with diarrhea G3 plus hand-foot syndrome (HFS) (G3)) an amendment was implemented to reduce the Sor dose from 400mg BID to once daily. In DL 1 after the amendment, 2 pts experienced a DLT (enteritis G3, dermatitis G3). Two pts in DL 2 suffered from a DLT (cystitis G3 plus HFS G3, cardiac ischemia G3). Further non dose-limiting G3 toxicities after the amendment were lymphopenia (G3) (1pt, DL 2) and hypocalcaemia (G3) (1 pt, DL 2). No Grade 4 toxicity was seen. DL 2 is the recommended dose for phase II. Conclusions: After reducing the Sor dose to 400mg once daily, neoadjuvant treatment with Sor in combination with full dose Cape and RT was tolerable and the toxicities manageable. [Table: see text]
Abstract 58: Therapeutically targeting the cell cycle in head and neck cancer
Authors: Ahmed Diab, Xu Chang, Michael Kao, Bruce Clurman, Denise Galloway, Mendez Eduardo
Journal: Clinical Cancer Research (2017)

Abstract Head and neck squamous cell carcinomas (HNSCC) have a complex mutational spectrum with tumor suppressor and cell cycle dysregulation as the most prominent features. Additionally, HPV infection has been shown to be a cause of some HNSCC, particularly oropharyngeal cancer, and it is increasing in the US. Our recent studies have established WEE1 inhibition as a new therapeutic strategy in HNSCC. WEE1 inhibition not only leads to premature mitosis by weakening the G2/M checkpoint but also causes replication stress in S-phase particularly in tumors with deficient TP53. Given that HPV infection causes genetic instability by inactivating tumor suppressor pathways (TP53 and Rb) and impairing proper DNA damage repair (DDR) response, we aim to explore targets that will synergize with WEE1 and decrease reliance on chemotherapy. To this end, we performed a q-PCR array profiling p53 dependent gene expression in a pair of isogenic HNSCC cell lines for p53 knockdown (vs wildtype control). Using a similar profiling technique in an isogenic pair of immortalized human oral keratinocytes (OKF4 cells) over expressing HPV16 E6/E7 proteins, we profiled the expression of DDR genes in response to DNA damage in wildtype vs. E6E7 expressing keratinocytes. A functional high-throughput siRNA library screen for DDR genes was performed to functionally validate the pathways identified. We looked for DDR genes that specifically sensitized p53 deficient HNSCC cells as well as E6/E7 expressing cells to WEE1 inhibition. TP53 deficient cells exhibited elevated levels of DDR related genes in response to DNA damage when compared to isogenic wildtype. We identified potential survival DDR pathways for E6E7- mediated transformation, targeting of which represents a novel therapeutic strategy. The DDR siRNA screen with WEE1 inhibition provided a functional validation for our findings. Gene ontology analysis of top 10% of WEE1 sensitizers identified BRCA1 related DNA damage response genes as top sensitizers for WEE1 inhibition in p53 deficient cells. Collectively, these results would help develop a new therapeutic paradigm for HPV-positive HNSCC by providing tailored mechanism-based therapies. Citation Format: Ahmed Diab, Xu Chang, Michael Kao, Bruce Clurman, Denise Galloway, Mendez Eduardo. Therapeutically targeting the cell cycle in head and neck cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; April 23-25, 2017; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(23_Suppl):Abstract nr 58.
Description of the periodontal pocket in preclinical models: limitations and considerations
Authors: Nikolaos Donos, Jung‐Chul Park, André Vajgel, Bruna de Carvalho Farias, Xanthippi Dereka
Journal: Periodontology 2000 (2017)

Abstract Establishment of periodontal health and regeneration of the lost periodontal tissues are always the ultimate goal of periodontal treatment. The development of new therapeutic approaches raises the necessity for appropriate experimental models that present periodontal structures and healing capability comparable to humans. Preclinical research and extrapolation of the data to human conditions remains a stage of great importance before the clinical application of the new biomaterials and techniques. Periodontal pockets/defects in preclinical models can be induced experimentally through acute or chronic or a combination of both (induced) modalities. The features of the created defects and those of humans vary greatly mostly due to the nature of the periodontal disease. This is an important point to take into account, since it is well recognized that the potential of periodontal therapy may be dependent on both the biological background and the defect morphology. This review provides insight into the commonly used preclinical models for the reproduction of the periodontal pocket and discusses the advantages and disadvantages of each model in terms of similarity to human conditions, standardization and reproducibility.
An actin cytoskeletal barrier inhibits lytic granule release from natural killer cells in patients with Chediak-Higashi syndrome
Authors: Aleksandra Gil-Krzewska, Mezida B. Saeed, Anna Oszmiana, Elizabeth R. Fischer, Kathryn Lagrue, William A. Gahl, Wendy J. Introne, John E. Coligan, Daniel M. Davis, Konrad Krzewski
Journal: Journal of Allergy and Clinical Immunology (2017)

Chediak-Higashi syndrome (CHS) is a rare disorder caused by biallelic mutations in the lysosomal trafficking regulator gene (LYST), resulting in formation of giant lysosomes or lysosome-related organelles in several cell types. The disease is characterized by immunodeficiency and a fatal hemophagocytic lymphohistiocytosis caused by impaired function of cytotoxic lymphocytes, including natural killer (NK) cells.We sought to determine the underlying biochemical cause of the impaired cytotoxicity of NK cells in patients with CHS.We generated a human cell model of CHS using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. We used a combination of classical techniques to evaluate lysosomal function and cell activity in the model system and super-resolution microscopy to visualize F-actin and lytic granules in normal and LYST-deficient NK cells.Loss of LYST function in a human NK cell line, NK92mi, resulted in inhibition of NK cell cytotoxicity and reproduced other aspects of the CHS cellular phenotype, including the presence of significantly enlarged lytic granules with defective exocytosis and impaired integrity of endolysosomal compartments. The large granules had an acidic pH and normal activity of lysosomal enzymes and were positive for the proteins essential for lytic granule exocytosis. Visualization of the actin meshwork openings at the immunologic synapse revealed that the cortical actin acts as a barrier for secretion of such large granules at the cell-cell contact site. Decreasing the cortical actin density at the immunologic synapse or decreasing the lytic granule size restored the ability of LYST-deficient NK cells to degranulate and kill target cells.The cortical actin and granule size play significant roles in NK cell cytotoxic function. We present evidence that the periodicity of subsynaptic actin is an important factor limiting the release of large lytic granules from NK cells from patients with CHS and could be a novel target for pharmaceutical intervention.
Synaptic weight set by Munc13-1 supramolecular assemblies
Authors: Hirokazu Sakamoto, Tetsuroh Ariyoshi, Naoya Kimpara, Kohtaroh Sugao, Isamu Taiko, Kenji Takikawa, Daisuke Asanuma, Shigeyuki Namiki, Kenzo Hirose
Journal: Nature Neuroscience (2017)
VR-CAP Alternating with Rituximab and High-Dose Cytarabine: An Effective First-Line Mantle Cell Lymphoma Regimen Prior to Autologous Stem Cell Transplant
Authors: Stephen D. Smith, Brian G. Till, Andrew J. Cowan, Sandra L. Kanan, Lauren Low, Ajay K. Gopal, Oliver W. Press, Brian T. Hill, Mazyar Shadman
Journal: Blood (2017)
Revisiting the Relationships Between Measures of Glycemic Control and Hypoglycemia in Continuous Glucose Monitoring Data Sets
Authors: Marga Gimenez, Amitai Jeremy Tannen, Monika Reddy, Vanessa Moscardo, Ignacio Conget, Nick Oliver
Journal: Diabetes Care (2017)

OBJECTIVE The Diabetes Control and Complications Trial (DCCT) identified an inverse relationship between HbA1c and severe hypoglycemia. We investigated the relationship between hypoglycemia and HbA1c in a large type 1 diabetes cohort on multiple daily injection or insulin pump therapy using blinded continuous glucose monitoring (CGM) data. The impact of real-time CGM on these relationships and how these relationships differ with biochemical definitions of hypoglycemia have also been assessed. RESEARCH DESIGN AND METHODS CGM data were obtained from the JDRF CGM randomized control trial. Baseline blinded CGM data were used to assess time in hypoglycemia in all individuals. End point data from the CGM intervention group were used to assess the impact of CGM. Percentage of time spent below 3.9, 3.3, 3.0, and 2.8 mmol/L were calculated and quadratic regression plots drawn. Relationships were analyzed visually, and ANOVA was used to assess relationships between glycemia and time below threshold. RESULTS J-shaped relationships were observed for all biochemical hypoglycemia thresholds, with the lowest hypoglycemia risk occurring at HbA1c values between 8.1 and 8.6% (65–70 mmol/mol). The use of an average of 5 days/week of CGM flattened the relationships for 3.3, 3.0, and 2.8 mmol/L, and ANOVA confirmed the loss of relationship for the 3.3 mmol/L threshold using CGM. CONCLUSIONS The relationship between hypoglycemia and HbA1c in a population with type 1 diabetes is J-shaped. Lower HbA1c values are still associated with increased hypoglycemia risk, although the magnitude of risk depends on biochemical threshold. Real-time CGM may reduce the percentage time spent in hypoglycemia, changing the relationship between HbA1c and hypoglycemia.